The University of Oxford announced on Sunday that it had begun injecting volunteers with a vaccine developed with astrogenica against the beta (“South Africa”) variant of the coronavirus, to measure its effectiveness in clinical trials.
Also read: “Vaccine is safe, effective and available”
Also read: Vaccine: 2nd dose very early in the pharmacy
She said in a statement that approximately 2,250 participants would be recruited in the United Kingdom, South Africa, Brazil and Poland as part of Phase II and III of these clinical trials in humans.
The vaccine candidate is currently using “viral vector” (adenovirus) technology, which is currently used worldwide against COVID-19.
“It is important to test booster doses of vaccines and vaccines against newer variants, and we are also prepared to stay ahead of the coronavirus pandemic if their use proves necessary,” commented Professor Andrew Pollard, Oxford Vaccine Group Director.
Provisional data from these clinical trials will be assessed later this year and submitted to regulators for assessment during the fast-track process.
In May, the British government launched clinical trials of the immune response obtained by the third dose of the COVID vaccine to promote recall in the United Kingdom, where contaminants are spreading the Delta (“Indian”) variant.